Peptides Derived from the Tight Junction Protein CLDN1 Disrupt the Skin Barrier and Promote Responsiveness to an Epicutaneous Vaccine
Matthew G. Brewer(University of Rochester Medical Center), Benjamin L. Miller(University of Rochester), Thomas A. Hilimire(University of Rochester Medicine), Luis Martínez‐Sobrido(Texas Biomedical Research Institute), Takeshi Yoshida(University of Rochester Medicine), Radha P. Pandya(University of Rochester Medicine), Elizabeth A. Anderson, Lisa A. Beck(University of Rochester Medicine), Anna De Benedetto(University of Rochester Medicine)
Cited by 21
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Cytokine modulation of atopic dermatitis filaggrin skin expression
|Journal of Allergy and Clinical Immunology|2007|1.1k